²é¿´: 762  |  »Ø¸´: 1
µ±Ç°Ö÷ÌâÒѾ­´æµµ¡£

rhett82

½ð³æ (СÓÐÃûÆø)

ÆÐÌá±¾ÎÞÊ÷,Ã÷¾µÒà·Ç̨,±¾À´ ...

[½»Á÷] GMP´Ê»ãÒ»

¸üÒÂÊÒ   Changing Room
Ò»¸ü     First Changing Room
ÊÖÏûÊÒ   Hands Disinfection Room
ÆøÕ¢ÊÒ   Airlock Room
½à¾ßÊÒ   Cleaning Tools Room
ÇåÏ´ÊÒ   Cleaning Room
Ä£¾ßÊÒ   Dies Room
ÄÚ°ü×°ÊÒ Immediate Package Room
°²È«ÃÅ   Emergency Door
Íâ°üÇåÊÒ Outer Package Removing Room
´æÁÏ¼ä   Storage Room of Raw Materials
·ÛËéÊÒ   Pulverizing Room
±¸ÁÏÊÒ   Materials Preparing Room
Ó²½ºÊÒ   Hard Capsules Filling Room
Èí½ºÊÒ   Soft Capsules Room
ÖÆÁ£¸ÉÔïÊÒ   Granulating and Drying Room
×Ü»ì¼ä   Blending Room
ÖмäÕ¾   Intermediate Station
ѹƬÊÒ   Tablets Room Compression Room
°üÒÂÊÒ   Coating Room
Å佬¼ä   Coating Mixture Preparing Room
ÂÁËܰü×°¼ä   Packing Room
´«µÝ´°   Transferring Window
Íâ°ü×°ÊÒ Outer Packing Room
ÕôÁóË®ÊÒ Water Purifying Room
ÖʼìÊÒ   Quality Control Room
ŨÅäÊÒ   Concentrated Solution Room
Ï¡ÅäÊÒ   Diluted Solution Room

BATCH PRODUCTION£ºÅúÁ¿Éú²ú£»·ÖÅúÉú²ú
BATCH PRODUCTION RECORDS£ºÉú²úÅúºÅ¼Ç¼
POST-OR PRE- MARKET SURVEILLANCE£ºÏúÊÛǰ»òÏúÊÛºó¼à¶½
INFORMED CONSENT£ºÖªÇéͬÒ⣨»¼Õß¶ÔÖÎÁÆ»òÊÜÊÔÕß¶ÔÒ½ÁÆÊÔÑéÁ˽âºó±íʾͬÒâ½ÓÊÜÖÎ
ÁÆ»òÊÔÑ飩
PRESCRIPTION DRUG£º´¦·½Ò©
OTC DRUG£¨OVER¡ªTHE¡ªCOUNTER DRUG£©£º·Ç´¦·½Ò©
U£®S£®PUBLIC HEALTH SERVICE£ºÃÀ¹úÎÀÉú¸£Àû²¿
Ò©Æ·ÖÆ±¸ preparation of drug products
Õë¶Ô     pertain to
ÈËÓÃÉúÎïÖÆÆ·   biological products for human use
²¹³ä      supplement
´úÌæÌõÀý    supersede the requlation
ÌáÒéÃâ³ý    proposed exemption
Ò»°ãÏúÊÛºÍÏû·Ñ   ordinarily marketed and consumed
ÃÀµÂ£¬Óŵ㣬ЧÁ¦  virtue
Áª°î×¢²á±í   FR/federal register
ÈËÓÃÎïÆ·  human foods
ÓÃÓÚ¼ø±ð£¬²â¶¨  shall be applied in determining
Éú²ú£¬¼Ó¹¤£¬°ü×°£¬Öü´æ  manufacture,process,pack,hold,
Ö°ÔðºÍȨÁ¦    responsibility and authority
Åú×¼ºÍ¾ÜÊÕ   approve or reject/withhold
¸´²éÉú²ú¼Ç¼    review production records
¶ÔqcÀ´Ëµ¿ÉÒÔ»ñµÃµÄ    shall be available to QC
Êʵ±µÄ      adequate
Ч¼ÛºÍº¬Á¿   strength
Ìṩ֤Ã÷Îļþ  shall be documented
·ûºÏ   conform to
ÖÆ¶©ÍêÉÆ   sound
ÿװ»õÁ¿  each shipment
±äÖʵĠ   is subject to deterioration
accommodation  (³µ£¬´¬£¬·É»úµÈµÄ)Ô¤¶¨ÆÌλ
ÅúºÅ  batch
Óк¦Î¢ÉúÎï  objectionable microorganism
ÁªºÏÅúºÅ   the number of units
׼ȷÐÔ£¬ÁéÃôÐÔ£¬ÌØÒìÐÔ£¬Öظ´ÐÔ
accuracy, sensitivity, specificity, and reproducibility
ÌØÕ÷£¬ÊôÐÔ attribute
ÅäÎé    reconstitution
Éè¼Æ   project
Ë³ÊÆÖÎÁÆÒ©Æ·   homeopathic drug products
¿ÉÅäÎéÐÔ    compatibility
±êÃ÷   purporting to
Ó¦³ÉÎIJ¢×ñÑ­    shall be in writing and shall be followed.
¿É¼ì³öˮƽ   detectable levels
ͨ¹ý²Î¿¼ÎÄÏ×¾ßÌ廯  incorporated by reference
¸±×÷Óà adeverse/side effect
ÀàÐÍ  type
»ì·Å   mixups
Ç©ÊÕ  receipt
´¦Àí  disposition
ÕýѹϹýÂË  be filtered under positive pressure  
²ãÁ÷»ò·Ç²ãÁ÷    laminar or nonlaminar;
ÎÞ¾ú»·¾³    aseptic conditions
ÕÕÃ÷   lighting
ͨ·ç¡¢¿ÕÆø¹ýÂË¡¢¿ÕÆø¼ÓÈÈÓëÀäÈ´   Ventilation, air filtration, air heating and cooling.
¿ÕÆøÊäËÍϵͳ   Air-handling systems
¸½½ü½¨ÖþÎï    immediate premises
רÓÃë½í  single-service towels
½øÁÏ   Charge-in
±êʾÁ¿»ò¹æ¶¨Á¿    labeled or established amount
ʵ¼Ê²úÁ¿   Actual yields
ÀíÂÛ²úÁ¿   theoretical yields
Éú²úÖÜÆÚ   the production of a batch of a drug product
Ò©Æ·µÄÒ»ÖÂÐÔºÍÍêÕûÐÔ    uniformity and integrity of drug products
±À½âʱ¼ä  Disintegration time
ÈÜÒºµÄ³ÎÃ÷¶È¡¢ÈܽâÍêÈ«ÐÔ¼°pHÖµ   Clarity, completeness, or pH of solutions
Îȶ¨ÐÔÆÀ¹À   variability estimates
װж  handling
NIH£¨NATIONAL INSTITUTE OF HEALTH£©£º£¨ÃÀ¹ú£©È«¹úÎÀÉúÑо¿Ëù
CLINICAL TRIAL£ºÁÙ´²ÊÔÑé
ANIMAL TRIAL£º¶¯ÎïÊÔÑé
ACCELERATED APPROVAL£º¼ÓËÙÅú×¼
FDA£¨FOOD AND DRUG ADMINISTRATION£©£º£¨ÃÀ¹ú£©Ê³Æ·Ò©Æ·¹ÜÀí¾Ö
IND£¨INVESTIGATIONAL NEW DRUG£©£ºÁÙ´²Ñо¿ÉêÇ루ָÉ걨½×¶Î£¬Ïà¶Ô
ÓÚNDA¶øÑÔ£©£»Ñо¿ÖеÄÐÂÒ©£¨Ö¸ÐÂÒ©¿ª·¢½×¶Î£¬Ïà¶ÔÓÚÐÂÒ©¶øÑÔ£¬¼´ÁÙ´²Ç°Ñо¿½áÊø£©
NDA£¨NEW DRUG APPLICATION£©£ºÐÂÒ©ÉêÇë
ANDA£¨ABBREVIATED NEW DRUG APPLICATION£©£º¼ò»¯ÐÂÒ©ÉêÇë
EPËߣ¨EXPORT APPLICATION £©£º³ö¿ÚÒ©ÉêÇ루ÉêÇë³ö¿Ú²»±»Åú×¼ÔÚÃÀ¹ú
ÏúÊÛµÄÒ©Æ·£©
TREATMENT IND£ºÑо¿ÖеÄÐÂÒ©ÓÃÓÚÖÎÁÆ
ABBREVIATED£¨NEW£©DRUG£º¼ò»¯ÉêÇëµÄÐÂÒ©
DMF£¨DRUG MASTER FILE£©£ºÒ©ÎïÖ÷Îļþ£¨³ÖÓÐÕßΪ½÷É÷Æð¼û¶ø×¼±¸µÄ±£
ÃÜ×ÊÁÏ£¬¿ÉÒÔ°üÀ¨Ò»¸ö»ò¶à¸öÈËÓÃÒ©ÎïÔÚÖÆ±¸¡¢¼Ó¹¤¡¢ °ü×°ºÍÖü´æ¹ý³ÌÖÐËù¼°µÄÉ豸¡¢Éú²ú¹ý³Ì»òÎïÆ·¡£Ö»ÓÐÔÚDMF³ÖÓÐÕß»òÊÚȨ´ú±íÒÔÊÚȨÊéµÄÐÎʽÊÚȨ¸øFDA£¬FDAÔÚÉó²éIND¡¢NDA¡¢ANDAʱ²ÅÄܲο¼ÆäÄÚÈÝ£©
HOLDER£ºDMF³ÖÓÐÕß
CFR£¨CODE OF FEDERAL REGULATION£©£º£¨ÃÀ¹ú£©Áª°î·¨¹æ
PANEL£º×¨¼ÒС×é
BATCH PRODUCTION£ºÅúÁ¿Éú²ú£»·ÖÅúÉú²ú
BATCH PRODUCTION RECORDS£ºÉú²úÅúºÅ¼Ç¼
POST-OR PRE- MARKET SURVEILLANCE£ºÏúÊÛǰ»òÏúÊÛºó¼à¶½
INFORMED CONSENT £ºÖªÇéͬÒ⣨»¼Õß¶ÔÖÎÁÆ»òÊÜÊÔÕß¶ÔÒ½ÁÆÊÔÑéÁ˽âºó±íʾͬÒâ½ÓÊÜÖÎÁÆ»òÊÔÑ飩
PRESCRIPTION DRUG£º´¦·½Ò©
OTC DRUG£¨OVER¡ªTHE¡ªCOUNTER DRUG£©£º·Ç´¦·½Ò©
U£®S£®PUBLIC HEALTH SERVICE£ºÃÀ¹úÎÀÉú¸£Àû²¿
NIH£¨NATIONAL INSTITUTE OF HEALTH£©£º£¨ÃÀ¹ú£©È«¹úÎÀÉúÑо¿Ëù
CLINICAL TRIAL£ºÁÙ´²ÊÔÑé
ANIMAL TRIAL£º¶¯ÎïÊÔÑé
ACCELERATED APPROVAL£º¼ÓËÙÅú×¼

Acceptance Criteria ¨C ½ÓÊÕ±ê×¼
½ÓÊÕ²âÊÔ½á¹ûµÄÊý×ÖÏÞ¶È¡¢·¶Î§»òÆäËüºÏÊʵÄÁ¿¶È±ê×¼¡£

Active Pharmaceutical Ingredient (API)(or Drug Substance) ¨C »îÐÔÒ©ÓÃ³É·Ö (Ô­ÁÏÒ©)
Ö¼ÔÚÓÃÓÚÒ©Æ·ÖÆÔìÖеÄÈκÎÒ»ÖÖÎïÖÊ»òÎïÖʵĻìºÏÎ¶øÇÒÔÚÓÃÓÚÖÆÒ©Ê±£¬³ÉΪҩƷµÄÒ»ÖÖ»îÐԳɷ֡£´ËÖÖÎïÖÊÔÚ¼²²¡µÄÕï¶Ï£¬ÖÎÁÆ£¬Ö¢×´»º½â£¬´¦Àí»ò¼²²¡µÄÔ¤·ÀÖÐÓÐÒ©Àí»îÐÔ»òÆäËüÖ±½Ó×÷Ó㬻òÕßÄÜÓ°Ïì»úÌåµÄ¹¦Äܺͽṹ¡£

API Starting Material ¨C Ô­ÁÏÒ©µÄÆðʼÎïÁÏ
ÓÃÔÚÔ­ÁÏÒ©Éú²úÖеģ¬ÒÔÖ÷Òª½á¹¹µ¥Ôª±»²¢Èë¸ÃÔ­ÁÏÒ©µÄÔ­ÁÏ¡¢ÖмäÌå»òÔ­ÁÏÒ©¡£Ô­ÁÏÒ© µÄÆðʼÎïÁÏ¿ÉÄÜÊÇÔÚÊг¡ÉÏÓÐÊÛ£¬Äܹ»¸ù¾ÝºÏͬ»òÉÌҵЭÒé´ÓÒ»¸ö»ò¶à¸ö¹©Ó¦ÉÌ´¦¹ºµÃ£¬»òÕß×Ô¼ºÉú²ú¡£Ô­ÁÏÒ©µÄÆðʼÎïÁÏͨ³£ÓÐÌØ¶¨µÄ»¯Ñ§ÌØÐԺͽṹ¡£

Batch (or Lot) ¨C Åú
ÓÉÒ»¸ö»òһϵÁй¤ÒÕ¹ý³ÌÉú²úµÄÒ»¶¨ÊýÁ¿µÄÎïÁÏ£¬Òò´ËÔڹ涨µÄÏÞ¶ÈÄÚÊǾùÒ»µÄ¡£ÔÚÁ¬ÐøÉú²úÖУ¬Ò»Åú¿ÉÄܶÔÓ¦ÓÚÓëÉú²úµÄÄ³Ò»ÌØ¶¨²¿·Ö¡£ÆäÅúÁ¿¿É¹æ¶¨ÎªÒ»¸ö¹Ì¶¨ÊýÁ¿£¬»òÔڹ̶¨Ê±¼ä¼ä¸ôÄÚÉú²úµÄÊýÁ¿¡£

Batch Number (or Lot Number) ¨C ÅúºÅ
ÓÃÓÚ±êʶһÅúµÄÒ»¸öÊý×Ö¡¢×ÖĸºÍ/»ò·ûºÅµÄΨһ×éºÏ£¬´ÓÖпÉÈ·¶¨Éú²úºÍÏúÊÛµÄÀúÊ·¡£

Bioburden ¨C ÉúÎï¸ºÔØ
¿ÉÄÜ´æÔÚÓÚÔ­ÁÏ¡¢Ô­ÁÏÒ©µÄÆðʼÎïÁÏ¡¢ÖмäÌå»òÔ­ÁÏÒ©ÖеÄ΢ÉúÎïµÄˮƽºÍÖÖÀà(ÀýÈ磬Ö²¡µÄ»ò²»Ö²¡µÄ)¡£ÉúÎï¸ºÔØ²»Ó¦µ±µ±×÷ÎÛȾ£¬³ý·Çº¬Á¿³¬±ê£¬»òÕß²âµÃÖ²¡ÉúÎï¡£

Calibration ¨C УÑé
Ö¤Ã÷ij¸öÒÇÆ÷»ò×°ÖÃÔÚÒ»Êʵ±µÄÁ¿³Ì·¶Î§ÄÚËù²âµÃµÄ½á¹ûÓëÒ»²ÎÕÕÎ»ò¿É×·Ëݵıê×¼Ïà±ÈÔڹ涨ÏÞ¶ÈÄÚ¡£

Computer System ¨C ¼ÆËã»úϵͳ
Éè¼Æ°²×°ÓÃÓÚÖ´ÐÐijһÏî»òÒ»×鹦ÄܵÄÒ»×éÓ²¼þÔª¼þºÍ¹ØÁªµÄÈí¼þ¡£

Computerized System ¨C ¼ÆËã»ú»¯ÏµÍ³
Óë¼ÆËã»úϵͳÕûºÏµÄÒ»¸ö¹¤ÒÕ»ò²Ù×÷¡£

Contamination ¨C ÎÛȾ
ÔÚÉú²ú¡¢È¡Ñù¡¢°ü×°»òÖØÐ°ü×°¡¢Öü´æ»òÔËÊä¹ý³ÌÖУ¬¾ß»¯Ñ§»ò΢ÉúÎïÐÔÖʵÄÔÓÖÊ»òÍâÀ´ÎïÖʽøÈë»òմȾԭÁÏ¡¢ÖмäÌå»òÔ­ÁÏÒ©¡£

Contract Manufacturer ¨C ЭÒéÖÆÔìÉÌ
´ú±íÔ­ÖÆÔìÉ̽øÐв¿·ÖÖÆÔìµÄÖÆÔìÉÌ¡£

Critical ¨C ¾ö¶¨ÐÔµÄ
ÓÃÀ´ÃèÊöΪÁËÈ·±£Ô­ÁÏÒ©·ûºÏ¹æ¸ñ±ê×¼£¬±ØÐë¿ØÖÆÔÚÔ¤¶¨·¶Î§ÄڵŤÒÕ²½Öè¡¢¹¤ÒÕÌõ¼þ¡¢²âÊÔÒªÇó»òÆäËüÓйزÎÊý»òÏîÄ¿¡£

Cross-Contamination ¨C ½»²æÎÛȾ
Ò»ÖÖÎïÁÏ»ò²úÆ·¶ÔÁíÒ»ÖÖÎïÁÏ»ò²úÆ·µÄÎÛȾ¡£

Deviation ¨C Æ«²î
¶ÔÅú×¼µÄÖ¸Áî»ò¹æ¶¨µÄ±ê×¼µÄÆ«Àë¡£

Drug (Medicinal) Product ¨C Ò©Æ·
¾­×îºó°ü×°×¼±¸ÏúÊÛµÄÖÆ¼Á(²Î¼ûQ1A)¡£

Drug Substance ¨C Ò©Îï
¼ûÔ­ÁÏÒ©

Expiry Date (or Expiration Date) ¨C ÓÐЧÆÚ
Ô­ÁÏÒ©ÈÝÆ÷/±êÇ©ÉÏ×¢Ã÷µÄÈÕÆÚ£¬Ôڴ˹涨ʱ¼äÄÚ£¬¸ÃÔ­ÁÏÒ©Ôڹ涨Ìõ¼þÏÂÖü´æÊ±£¬ÈÔ·ûºÏ¹æ¸ñ±ê×¼£¬³¬¹ýÕâÒ»ÆÚÏÞÔò²»Ó¦µ±Ê¹Óá£

Impurity ¨C ÔÓÖÊ
´æÔÚÓÚÖмäÌå»òÔ­ÁÏÒ©ÖУ¬Èκβ»Ï£ÍûµÃµ½µÄ³É·Ö¡£

Impurity Profile ¨C ÔÓÖʸſö
¶Ô´æÔÚÓÚÒ»ÖÖÔ­ÁÏÒ©ÖеÄÒÑÖªºÍδ֪ÔÓÖʵÄÃèÊö¡£

In-Process Control (or Process Control) ¨C ÖÐ¼ä¿ØÖÆ
Éú²ú¹ý³ÌÖÐΪ¼à²â£¬ÔÚ±ØÒªÊ±µ÷½Ú¹¤ÒÕºÍ/»ò±£Ö¤ÖмäÌå»òÔ­ÁÏÒ©·ûºÏÆä¹æ¸ñ¶ø½øÐеļì²é¡£

Intermediate ¨C ÖмäÌå
Ô­ÁÏÒ©¹¤ÒÕ²½ÖèÖвúÉúµÄ¡¢±ØÐë¾­¹ý½øÒ»²½·Ö×ӱ仯»ò¾«ÖƲÅÄܳÉΪԭÁÏÒ©µÄÒ»ÖÖÎïÁÏ¡£ÖмäÌå¿ÉÒÔ·ÖÀë»ò²»·ÖÀë¡£(×¢£º±¾Ö¸ÄÏֻɿ¼°¸Ã¹«Ë¾¶¨ÒåΪԭÁÏÒ©Éú²úÆðʼµãÒÔºóÉú²úµÄÖмäÌå¡£)

Lot ¨C Åú
¼ûÅú(Batch)¡£
»Ø¸´´ËÂ¥
ÆÐÌá±¾ÎÞÊ÷,Ã÷¾µÒà·Ç̨,±¾À´ÎÞÒ»Îï,ºÎ´¦Èdz¾°££®
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

kianna

Ìú³æ (³õÈëÎÄ̳)

2Â¥2007-04-02 15:40:37
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
Ïà¹Ø°æ¿éÌø×ª ÎÒÒª¶©ÔÄÂ¥Ö÷ rhett82 µÄÖ÷Ìâ¸üÐÂ
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[²©ºóÖ®¼Ò] ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼± +6 3dfhjxgsh7 2026-02-22 9/450 2026-02-23 07:49 by w4l55oybr1
[¿¼²©] ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼± +4 khieu8v8m0 2026-02-22 4/200 2026-02-23 06:46 by jsjzfl
[ÂÛÎÄͶ¸å] ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼± +3 w89i99eaeh 2026-02-22 4/200 2026-02-23 06:36 by w4l55oybr1
[²©ºóÖ®¼Ò] ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼± +4 khieu8v8m0 2026-02-22 5/250 2026-02-23 06:34 by w4l55oybr1
[¹«Åɳö¹ú] ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼± +3 khieu8v8m0 2026-02-22 5/250 2026-02-23 06:29 by w4l55oybr1
[˶²©¼ÒÔ°] ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼± +4 khieu8v8m0 2026-02-22 8/400 2026-02-23 06:24 by w4l55oybr1
[¿¼ÑÐ] ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼± +4 usprnugpzw 2026-02-21 10/500 2026-02-23 04:58 by 5jlh3qtdvx
[ÂÛÎÄͶ¸å] ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼± +3 khieu8v8m0 2026-02-22 6/300 2026-02-23 02:08 by 5jlh3qtdvx
[¿¼²©] ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼± +5 3dfhjxgsh7 2026-02-22 6/300 2026-02-23 02:04 by 5jlh3qtdvx
[½Ìʦ֮¼Ò] °æÃæ·Ñ¸Ã½»Âð +7 Æ»¹ûÔÚÄÄÀï 2026-02-22 8/400 2026-02-22 22:37 by otani
[»ù½ðÉêÇë] »ù½ðÕýÎÄ30Ò³Ö¸µÄÊDZ¨¸æÕýÎÄ»¹ÊÇÕû¸öÉêÇëÊé +5 successhe 2026-02-16 6/300 2026-02-22 21:38 by ɽÎ÷Ðü¿ÕË¿ÕÐüÎ
[»ù½ðÉêÇë] ÃæÉÏ¿ÉÒÔ³¬¹ý30Ò³°É£¿ +4 °¢À­¹±aragon 2026-02-22 4/200 2026-02-22 21:22 by ɽÎ÷Ðü¿ÕË¿ÕÐüÎ
[½Ìʦ֮¼Ò] ΪʲôÖйú´óѧ½ÌÊÚÃÇË®ÁËÄÇô¶àËùνµÄ¶¥»á¶¥¿¯£¬µ«»¹ÊÇ×ö²»³öÓîÊ÷»úÆ÷ÈË£¿ +5 »¶ÀÖËÌÒ¶Ýè 2026-02-21 5/250 2026-02-22 21:15 by ɽÎ÷Ðü¿ÕË¿ÕÐüÎ
[ÂÛÎÄͶ¸å] ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼± +4 usprnugpzw 2026-02-21 6/300 2026-02-22 19:48 by w89i99eaeh
[¿¼ÑÐ] ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼± +3 3dfhjxgsh7 2026-02-22 4/200 2026-02-22 16:52 by khieu8v8m0
[ÕÒ¹¤×÷] ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼± +3 usprnugpzw 2026-02-22 3/150 2026-02-22 16:37 by khieu8v8m0
[¹«Åɳö¹ú] ÊÛSCIÒ»ÇøÎÄÕ£¬ÎÒ:8 O5 51O 54,¿ÆÄ¿ÆëÈ«,¿É+¼± +3 usprnugpzw 2026-02-21 4/200 2026-02-22 16:27 by khieu8v8m0
[»ù½ðÉêÇë] ¡°ÈËÎÄÉç¿Æ¶øÂÛ£¬Ðí¶àѧÊõÑо¿»¹Ã»ÓдﵽÃñ¹úʱÆÚµÄˮƽ¡± +4 ËÕ¶«ÆÂ¶þÊÀ 2026-02-18 5/250 2026-02-22 16:07 by liangep1573
[»ù½ðÉêÇë] ½ñÄê´ºÍíÓм¸¸ö½ÚÄ¿ºÜ²»´í£¬µãÔÞ£¡ +11 ˲ϢÓîÖæ 2026-02-16 12/600 2026-02-21 21:14 by lq493392203
[»ù½ðÉêÇë] ÌåÖÆÄÚ³¤±²ËµÌåÖÆÄÚ¾ø´ó²¿·ÖÒ»±²×ÓÔڵײ㣬ÈçͬÄãÃÇÒ»Ñù´ó²¿·ÖÆÕͨ½ÌʦæÇÒÊÕÈëµÍ +9 ˲ϢÓîÖæ 2026-02-20 12/600 2026-02-21 10:39 by »¶ÀÖËÌÒ¶Ýè
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û